JAMA Netw Open

Does cannabis use impact nicotine vaping cessation in young adults?

December 16, 2025

A secondary analysis of a randomized trial (N = 261; ages 16 to 25) found that baseline cannabis use, regardless of frequency or severity, didn’t reduce nicotine vaping abstinence rates. Even among participants using cannabis 4 to 7 days per week, cessation outcomes were similar (adjusted odds ratio, 1.14; 95% confidence interval, 0.51–2.57). Varenicline combined with behavioral support significantly improved quit rates compared with behavioral support alone, and its efficacy was unaffected by cannabis co-use (interaction P=0.32).

Clinical takeaway: Concurrent cannabis use doesn’t appear to be a barrier to offering varenicline for nicotine vaping cessation in adolescents and young adults.

Source:

Gilman JM, et al. (2025, December 12). JAMA Netw Open. Cannabis Use and Nicotine Vaping Cessation Outcomes: A Secondary Analysis of a Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41385228/